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ABSTRACT 
Synaptic degeneration is one of the earliest characteristics of Alzheimer disease (AD). The 
amyloid β-peptide (Aβ) plays a critical role in the pathology of AD and therefore thorough 
understanding of its production and functions is of outmost importance. Aβ is generated by 
sequential cleavage of the amyloid precursor protein (APP) by the β-secretase BACE1 and 
by the γ-secretase. In an alternative, non-amyloidogenic pathway, APP is cleaved by the α-
secretase ADAM10 instead of BACE1, precluding Aβ formation. Increased synaptic 
activity has been associated with increased secretion of Aβ and since our lab had previously 
shown that Aβ can be produced at the synapse, we hypothesised that Aβ is produced inside 
synaptic vesicles and released through normal synaptic vesicle exocytosis. We found that 
small amounts of Aβ can be produced in synaptic vesicles, although these vesicles do not 
appear to be the main site of Aβ production. To study the secretion, synaptosomes 
(functional, pinched off, nerve endings) were isolated from rat brain and we could 
demonstrate that Aβ is continuously secreted from synapses in an activity-independent 
manner through a mechanism that is distinct from normal neurotransmitter release. While 
further investigating the highly pure synaptic vesicles, both ADAM10 and BACE1, as well 
as their cleavage products, APP C-terminal fragments (CTFs), were found to be greatly 
enriched in these vesicles compared to total brain homogenate. Yet, presenilin was the only 
enriched component of the γ-secretase complex. In addition, these Western blotting 
findings were confirmed by in situ proximity ligation assay (PLA) showing close proximity 
of both ADAM10 and BACE1 to the synaptic vesicle marker synaptophysin in intact 
mouse primary hippocampal neurons. Active γ-secretase, on the other hand, only gave rise 
to few PLA-signals, indicating that the first cleavage step in Aβ production takes place in 
synaptic vesicles while γ-secretase cleavage takes place elsewhere. Subsequently the 
synaptic location of the secretases was confirmed also in adult rat and human brain. Again 
using PLA, we could demonstrate that both ADAM10 and BACE1 were in close proximity 
to both synaptophysin and the postsynaptic density marker PSD-95 as well as to their 
substrate APP in both human and rat adult brain hippocampus and cortex. Also APP was in 
close proximity to both synaptophysin and PSD-95.  
In addition to the known synaptotoxicity of Aβ, a number of studies have implied important 
and toxic roles for other APP-derived fragments, such as CTF-β or the synaptotoxic Aα-η. 
Alternative cleavage of APP by η-secretase gives rise to CTF-η, which is further cleaved to 
Aα-η by ADAM10. However, which of these fragments that is most abundant in AD brain 
had, to our knowledge, not been elucidated. When performing SDS-PAGE and Western 
blotting we found that a 25 kDa CTF (likely corresponding to CTF-η) was abundant in 
human brain but present at much lower levels in rat and mouse brain. The 25 kDa CTF was 
also present in macaque and guinea pig brain but the levels of this fragment was not 
increased in the brain of a mouse model overexpressing the human APP gene with a 
Swedish/London mutation. This implies that it is the environment in the human brain, 
rather than the human APP gene itself, that determines whether the 25 kDa CTF is formed 
or not. Furthermore, we investigated whether AD patients have altered levels of the 25 kDa 
CTF in their brains but could not detect any significant differences between AD and control 
brain homogenate. 
Altogether, this thesis has contributed with new knowledge about synaptic release of Aβ 
and the synaptic localisation of the APP processing enzymes. It has thus highlighted the 
complexity and species differences of APP processing and its regulation. Implementation of 
this knowledge may facilitate future development of more specific and efficient treatment 
strategies for AD. 
  
  
POPULAR SCIENCE SUMMARY 
 
English 
Synapses are the chief components responsible for the communication between nerve cells. 
In Alzheimer disease the synapses, and eventually whole nerve cells, degenerate and die. This 
affects cognition and causes impairment in memory, disillusion and problems with coping 
with everyday tasks.  The amyloid β-peptide (Aβ) is considered to have a pivotal role in the 
course of the disease and is formed by cleavage of the amyloid precursor protein (APP) by 
first the β-secretases BACE1 and then the γ-secretase complex. No Aβ is formed if APP is 
cleaved by the α-secretase ADAM10 instead of BACE1. In order to better understand Aβ 
production and possibly regulate it as treatment for Alzheimer disease, it is important to find 
out where the production takes place and thereby also where in the nerve cells the proteins 
involved in the production are located.  
In two of the papers in this thesis the synaptic location of ADAM10 and BACE1 were 
examined and it was demonstrated that both of them are located both presynaptically (in the 
part of the nerve cell that sends out signals) and postsynaptically (in the part of the nerve cell 
that receives signals). This is somewhat controversial since it was previously assumed that 
ADAM10 is located mainly in the postsynaptic part and BACE1 mainly in the presynaptic 
part of the nerve cell. It was also demonstrated that active γ-secretase is present at much 
lower levels in the presynaptic vesicles in which we demonstrated that ADAM10 and BACE1 
are enriched. This implies that, in order for Aβ to be produced, CTF-α and -β (the fragments 
produced by ADAM10 and BACE1 cleavage of APP) need to be transported from the 
synaptic vesicles to another (yet unknown) synaptic structure where γ-secretase is located. 
In the first paper of the thesis we attempted to determine how Aβ is secreted from synapses. 
Although we were unable to identify the mechanism behind Aβ secretion, we could 
demonstrate that Aβ is continuously secreted from neurons through a mechanism different 
from normal neurotransmitter release.  
During the work with the first parts of this thesis, we found that a specific APP-derived 
fragment with a molecular weight of 25 kDa (“25 kDa CTF”) was abundant in human brain 
but not in rat brain. It is possible that this 25 kDa CTF is identical to the recently identified 
CTF-η. Since this fragment, together with Aβ, may have negative effects on synapses and 
brain function, we decided to examine it further. The 25 kDa CTF was always found in 
human brain while it was hardly detectable in rat and mouse brain. However, people with 
Alzheimer disease did not have different levels of this fragment in their brains compared to 
control persons. We also found this fragment in the brain of macaque and guinea pig, which 
both are more evolutionary close to humans than rats and mice. Our results may possibly 
explain why humans, but not rats or mice, develop AD. When transferring results from 
animal experiments to human medicine, species differences need to be more carefully 
considered. 
This thesis contributes with increased knowledge of the mechanisms behind APP cleavage 
and the fragments thereby produced. This is of great importance for future development of 
treatment which may delay, or even prevent, the cognitive impairment in Alzheimer disease. 
 
Svenska 
Synapser är grundstrukturen för kommunikation mellan nervceller och i Alzheimers sjukdom 
bryts både synapser och sedan hela nervceller ner och förtvinar. Detta påverkar den kognitiva 
förmågan och leder till försämrat minne, desillusion och problem med att klara dagliga 
sysslor. Amyloid β-peptiden (Aβ) antas ha en framträdande roll i sjukdomsförloppet och den 
bildas genom att amyloid prekursorproteinet (APP) klyvs på olika ställen av först β-sekretaset 
BACE1 och sedan av γ-sekretasenzymet. Om APP klyvs av α-sekretaset ADAM10 istället 
för av BACE1 bildas inget Aβ.  
För att bättre förstå Aβ-produktionen och eventuellt kunna reglera den i medicinskt syfte är 
det viktigt att ta reda på var den sker och därmed var i nervcellerna de olika proteinerna som 
är involverade i produktionen finns. I två delarbeten i denna avhandling undersöker vi den 
synaptiska lokaliseringen av ADAM10 och BACE1 och visar att de finns både pre-synaptiskt 
(i den del av nervcellen som sänder ut signaler) och postsynaptiskt (i den del av nervcellen 
som tar emot signaler). I tidigare forskning har det antagits att ADAM10 återfinns i den 
postsynaptiska delen och BACE1 i den presynaptiska delen. Vi visar också att det aktiva γ-
sekretaset till största del inte finns i de presynaptiska vesiklar där vi visade att ADAM10 och 
BACE1 finns. Detta tyder på att för att Aβ ska kunna bildas så måste CTF-α och -β (de 
fragment som bildas vid ADAM10- och BACE1-klyvning av APP) transporteras från dessa 
vesiklar till den (ännu okända) synaptiska struktur där γ-sekretaset finns.  
  
I det första delarbetet undersökte vi hur Aβ utsöndras från synapser. Mekanismen bakom 
utsöndringen kunde inte påvisas men vi kunde visa att Aβ inte utsöndras från nervceller på 
samma sätt som vanliga signalsubstanser. 
Under arbetet med de första delarbetena i denna avhandling upptäckte vi att ett specifikt 
APP-fragment med en molekyl-vikt på 25 kDa (”25 kDa CTF”) är anrikat i människohjärna 
men knappt finns i råtthjärna. Det är möjligt att detta 25 kDa CTF och det nyligen 
identifierade CTF-η är samma fragment. I det sista delarbetet undersökte vi förekomsten av 
detta 25 kDa CTF närmare eftersom detta fragment tillsammans med Aβ kan förorsaka 
negativa effekter på synapser och hjärnans funktion. 25 kDa CTF återfanns alltid i human-
hjärna medan det knappt gick att detektera i hjärna från råtta och mus. Dock kunde vi inte 
urskilja skillnader i nivåerna av detta fragment mellan kontrollpersoner och personer med 
Alzheimers sjukdom. Även i hjärnan hos makaker och marsvin, som båda evolutionsmässigt 
är närmare människan än råtta och mus, återfanns 25 kDa CTF. Artskillnader i nivåerna av 
detta fragment kan vara en förklaring till varför människor men inte råttor och möss får 
Alzheimers sjukdom. Kunskapen om denna artskillnad är viktig att ta i beaktande vid läke-
medelsutveckling som baseras på djurförsök. 
Denna avhandling bidrar till ökad förståelse av mekanismerna bakom APP-klyvning och de 
olika fragment som därmed kan bildas. Detta är av stor betydelse för framtida utveckling av 
medicin som kan fördröja eller rentav förhindra uppkomsten av den kognitiva nedsättningen i 
Alzheimers sjukdom. 
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1 INTRODUCTION 
1.1 ALZHEIMER DISEASE AND DEMENTIA 
Alzheimer disease (AD) is the most common neurodegenerative disorder and cause of 
dementia, comprising up to 70 % of all dementia cases (Prince et al. 2013). Vascular 
dementia, Frontotemporal dementia, Dementia with Lewy Bodies and Parkinson’s disease 
dementia are other common types of dementia, all of which are associated with abnormal 
accumulation and deposition of toxic protein aggregates in the brain. The appearance of 
these aggregates often precede the clinical symptoms by many years (Ross and Poirier 
2004). The clinical manifestations of dementia are chronic and progressive worsening of 
cognitive function. After early and subtle impairments in memory formation and recall, the 
symptoms gradually worsen and begin to affect also other cognitive functions, such as 
behaviour, orientation, language and executive functions including planning, judgement 
and problem solving (Prince et al. 2013).  
Around 50 million people suffer from dementia and there are almost 10 million new cases 
each year (WHO, 2017). The main reason for this dramatic increase in dementia is the 
aging population in the world, especially in low- and middle-income countries (WHO, 
2017; Prince et al., 2013). Accordingly, dementia is a huge socioeconomic burden, costing 
the society 818 billion USD in 2015, which is 1.1 % of the world’s gross domestic product 
(Winblad et al., 2016; WHO, 2017). The cost of dementia is unevenly distributed and 
affects low- and middle-income countries most. Consequently, the unequal burden of 
dementia will largely be affecting countries that have less awareness of the disease and 
lower capacity to handle it. However, policymakers in the West are starting to appreciate 
the dramatic effect of dementia on society and focus resources on combating dementia from 
different angles. To raise awareness of dementia as well as to encourage and promote 
national and international action, the World Health Organization (WHO), together with 
Alzheimer’s Disease International, has published the report “Dementia: a public health 
priority” (Winblad et al., 2016; WHO, 2017). The fact that WHO has declared dementia a 
public health priority is a welcomed progression and will hopefully have noticeable effects 
in society. However, taking the suffering and psychological burden of the patients and their 
family and caregivers into account, focusing on preventing and treating dementia is, 
evidently, not primarily of economic interest.  
 2 
Figure 1. The neuropathological hallmarks of Alzheimer 
disease. Silver staining of a post mortem AD brain showing 
amyloid plaques (arrows) and neurofibrillary tangles 
(arrow-heads). Adapted from Winblad et al. (2016). 
1.1.1 Stages of Alzheimer disease  
Individuals who experience cognitive decline or impaired memory although they cannot be 
clinically diagnosed are classified as having subjective cognitive impairment (SCI). Mild 
cognitive impairment (MCI), on the other hand, is a pre-stage of dementia, yet not all MCI 
patients develop dementia or AD. The cognition state between dementia and normal aging 
are described as MCI. MCI patients display objective cognitive decline, yet they still 
function in their everyday lives and usually do not need much extra assistance or care 
(Knopman and Petersen 2014). 
A family history of dementia is linked to increased risk of developing AD. Genetically 
autosomal dominant inherited, familial AD (FAD) is caused by mutations in three genes 
(APP, PSEN1 and PSEN2), all of which influence the processing of the amyloid precursor 
protein (APP) into the amyloid β-peptide (Aβ) which aggregates and make up the amyloid 
plaques which are characteristic hallmarks in the brains of AD patients. AD-associated 
mutations in these genes lead to aggregation of Aβ and aggressive early onset of the 
disease. FAD accounts for around 5 % of the AD cases while the rest are classified as 
sporadic AD (Bagyinszky et al. 2014; Winblad et al. 2016).  
1.1.2 Neuropathology  
AD is characterised by the presence in 
the brain of extracellular amyloid 
plaque depositions and intraneuronal 
tangles (Fig 1). However, these patho-
logical hallmarks are often preceded by 
synaptic dysfunction and degeneration, 
which is one of the earliest events in 
the pathology of AD (Knobloch and 
Mansuy 2008). The amyloid plaques in 
the brains of AD patients are made up 
of aggregated, fibrillar forms of 
synaptotoxic Aβ while the neuro-
fibrillary tangles (NFTs) consists of 
hyperphosphorylated tau protein (Selkoe 2011). Degeneration of neurites and eventually 
neuronal death cause brain atrophy which often is prominent at later stages of the disease 
progression (Knobloch and Mansuy 2008). Since the correlation between amyloid plaque 
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density and cognitive impairment is poor, it is evident that also other pathological features 
are involved (Soldano and Hassan 2014). The best correlation to cognitive decline in AD is 
synaptic loss (Terry et al. 1991), yet, the mechanisms behind the synaptic degeneration are 
still unclear.  
1.1.2.1 Tau  
As mentioned above, NFTs are pathological hallmarks of AD alongside the amyloid 
plaques. These intraneuronal NFTs consist of aggregated fibrillar forms of the microtubule-
associated protein tau (Nisbet et al. 2015). Under normal physiological conditions tau 
stabilises microtubules, regulates axonal transport and functions as a scaffolding protein by 
interacting with a variety of proteins. However, during the pathology of AD, tau becomes 
hyperphosphorylated, loses its physiological function and starts to aggregate (Brandt and 
Leschik 2004). Misfolded, aggregated and hyperphosphorlylated tau is unable to exert its 
role as a transport protein and may even disrupt the overall cellular trafficking. This impairs 
the transport of essential receptors and mitochondria to the synapses, with detrimental 
effects on synaptic function (Ebneth et al. 1998; Kanaan et al. 2011). Hyperphosphorylated, 
dysfunctional tau also redistributes from the axons into somatodendritic compartments 
(Götz et al. 1995). However, analysing synaptoneurosome preparations, Tai et al. (2012) 
demonstrated both pre- and postsynaptic localisation of tau in both AD and control human 
brain.  
Some of the toxic effects of Aβ are believed to be exerted via tau and there is considerable 
crosstalk between the toxic versions of these two proteins. Aβ and tau have both separate 
and common, synergistic pathological functions in AD (Nisbet et al. 2015). Injection into 
rat brain of Aβ extracted from human plaque cores caused tau pathology and neuronal loss 
(Frautschy et al. 1991). Reducing endogenous levels of tau in AD transgenic mice, without 
altering Aβ levels, reversed memory impairment, reduced early mortality and protected 
against excitotoxicity (Roberson et al. 2007). Moreover, double transgenic mice with both 
APP and tau mutations exhibit more tau pathology than the single transgenic mice, 
although tau levels are not increased (Lewis et al. 2001). The same is true for transgenic 
mice with mutated APP, presenilin and tau which also show increased neuronal loss in the 
hippocampus (Héraud et al. 2014). Consequently, it appears as if Aβ toxicity is tau-
dependent. However, tau may also sensitise synapses to Aβ toxicity which is further 
amplified by the effect of Aβ on tau, causing a vicious cycle (Ittner and Götz 2011). 
 4 
1.1.2.2 Inflammation 
Chronic or abnormally activated inflammation can be detrimental and many 
neurodegenerative disorders, e.g. multiple sclerosis, Parkinson’s disease, and AD, are 
associated with neuroinflammation (Graeber et al. 2011). In the AD brain, amyloid plaques 
as well as NFTs are surrounded by activated microglia and reactive astrocytes (Beach et al. 
1989; Itagaki et al. 1989; Masliah et al. 1991) and both the complement and the innate 
immune system are activated in AD brains (Pimplikar 2014). Systemic inflammation has 
also been linked to AD (Pimplikar 2014) and many of the AD-associated genes identified 
by genome-wide association studies are involved in the inflammatory response (Tosto and 
Reitz 2013). In addition, several studies have shown that receiving anti-inflammatory 
treatment is associated with lower prevalence of AD (Rich et al. 1995; Etminan et al. 2003; 
McGeer et al. 2017) though other studies imply that the prevalence of AD is not affected by 
anti-inflammatory treatment (Gupta et al. 2015). Nevertheless, whether inflammation is a 
risk factor and potential cause of AD or a consequence of the pathological changes in AD is 
not clear.  
1.1.2.3 Energy metabolism, oxidative stress and mitochondria 
Oxidative stress is a result of imbalance in the production of reactive oxygen species (ROS) 
and the ability of the cell to clear them. Oxidative stress is a common feature of dysfunctional 
neurons already at an early stage of AD. This is considered to be caused by impaired 
mitochondrial function (Zhu et al. 2006) which is detrimental to neurons since the 
mitochondria, which are particularly abundant at the presynapse, provide the energy needed 
for neuronal function, especially neurotransmission. Positron emission tomography (PET) 
reveals evident decrease in the uptake of 2-[18F]fluoro-2-deoxy-D-glucose ([18F]FDG) in the 
brains of AD patients compared to controls, indicating decreased energy consumption in 
specific, pathology affected regions of their brain (Heiss et al. 1991; Frisoni et al. 2013). 
Mitochondrial dysfunction leads to decreased ATP production, increased production of ROS 
as well as reduced Ca2+ buffer capacity which affects neurotransmission (Bhat et al. 2015; 
Zhu et al. 2006; Ankarcrona et al. 2010). In addition, inappropriately activated apoptosis in 
the AD brain may be caused by death factors released from damaged mitochondria (Dawson 
and Dawson 2017).  
Mitochondrial dysfunction in AD is associated with Aβ (Zhu et al. 2006; Ankarcrona et al. 
2010). Aβ accumulates in mitochondria both in AD patients and transgenic animal models 
of AD (Lustbader et al., 2004; Manczak et al., 2006). The γ-secretase components are 
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found in mitochondria (Hansson et al. 2004) and Aβ can be produced at mitochondria-
endoplasmic reticulum (ER) contact sites (Schreiner et al. 2015). Aβ interacts with several 
mitochondrial proteins, thereby directly affecting mitochondrial function and subsequently 
contributing to oxidative stress (Lustbader et al., 2004; Manczak et al., 2006; Ankarcrona, 
Mangialasche and Winblad, 2010). 
1.1.3 APP processing and the amyloid β-peptide 
Aβ is a proteolytic product of APP. β- and γ-secretase generate Aβ by sequential cleavage 
of APP. After β-secretase cleavage, soluble APPβ (sAPPβ) and a C-terminal fragment of 
APP (CTF-β) are produced. CTF-β is further cleaved by γ-secretase, yielding Aβ and the 
intracellular domain AICD (Fig 2) (Vassar et al. 2009; Selkoe 2011). In a non-
amyloidogenic pathway, APP is cleaved by α-secretase instead of β-secretase, generating 
CTF-α and sAPPα. CTF-α will be cleaved into a P3 fragment by the γ-secretase complex 
(Fig 2). In contrast to Aβ, P3 is not prone to aggregate and have no known toxic effect 
(Postina et al. 2004; Kuhn et al. 2010).  
 
Figure 2. Processing of the amyloid precursor protein (APP). The first cleavage of APP by α- or β-
secretase generates soluble APP fragments (sAPPα and sAPPβ) and the APP C-terminal fragments CTF-α and 
CTF-β. The CTFs are further cleaved by γ-secretase generating the APP intracellular domain (AICD) as well 
as Aβ (in the amyloidogenic pathway, left) or the P3 fragment (in the non-amyloidogenic pathway, right). 
(Adapted from O’Brien and Wong 2011). 
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APP is a single-pass transmembrane protein which under physiological conditions mainly 
is processed in the non-amyloidogenic pathway. APP and sAPPα are important for the 
regulation of neural development, neurite outgrowth and guidance and for synapse 
formation (Soldano and Hassan 2014).  
Since APP is processed by γ-secretase in a stepwise manner, the Aβ-peptide may be of 
varying length, Aβ40 being the most common while Aβ42 is more toxic and prone to 
aggregate. However, other species, such as Aβ43 or N-terminally truncated Aβ, also exist 
(Vetrivel and Thinakaran 2006). Soluble, oligomeric forms of Aβ contribute more to AD 
pathology than fibrillar forms and also correlate better with cognitive decline than plaque-
associated Aβ (McLean et al. 1999; Näslund et al. 2000). Although extracellular amyloid 
plaques are hallmarks of AD, intracellular accumulation of Aβ, especially in neurites and 
synapses, are more toxic and cause synaptic dysfunction (Takahashi et al. 2002; Bayer and 
Wirths 2010; Tampellini and Gouras 2010; Gouras et al. 2012).  Neurons from both 
sporadic AD and FAD patients are enriched in intraneuronal Aβ42 and have increased 
Aβ42/40 ratio (Aoki et al. 2008).  
1.1.4 The APP processing secretases 
The major β-secretase of neurons is the β-site APP cleaving enzyme 1 (BACE1) which is 
an aspartic protease active in acidic environments, mainly endosomes and the trans-golgi 
network (Kinoshita et al. 2003; Yan and Vassar 2014; Kandalepas and Vassar 2014). Apart 
from BACE1, other enzymes with β-secretase activity have also been suggested, such as 
Cathepsin D (Schechter and Ziv 2008) and Cathepsin B (Hook et al. 2005). Yet BACE1 
activity on APP is most relevant for AD pathology since BACE1 knock-out animals do not 
display amyloid pathology and have no production of Aβ in their brain (Kandalepas and 
Vassar 2014). Synaptic BACE1 is primarily considered to be localised to the presynaptic 
compartment and BACE1 in enriched presynaptically at the mossy fibres in the stratum 
lucidum in the CA3 region of the hippocampus (Kandalepas et al. 2013). Del Prete et al. 
(2014) have found BACE1 also in synaptic vesicles (SVs).  
γ-secretase is a transmembrane complex consisting of presenilin1 (PS1) or PS2, nicastrin, 
anterior pharynx defective-1 (Aph-1) and presenilin enhancer-2 (Pen-2) and it cleaves its 
substrates within the membrane. The γ-secretase complex cleaves numerous type I 
transmembrane proteins in addition to APP, such as Notch, N-cadherin and ephrinB 
(Gertsik et al. 2015). The active γ-secretase complex has been observed to localise both pre- 
and postsynaptically (Schedin-Weiss et al. 2016). Inhibiting γ-secretase cleavage of APP 
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would reduce Aβ levels and consequently inhibitors and modulators of γ-secretase have 
been developed as potential AD therapy. Still, no γ-secretase inhibitors (GSIs) or γ-
secretase modulators (GSMs) have had success in in clinical trials, likely due to lack of 
effect or adverse effects caused by inhibition of the cleavage of other γ-secretase substrates, 
mainly Notch (Mikulca et al. 2014; Bachurin et al. 2017). Inhibition of γ-secretase will also 
lead to accumulation of CTF-β which probably has toxic effects on neurons (see section 
1.1.6), possibly contributing to the adverse effects caused by γ-secretase inhibition. 
The main α-secretase of neurons is a disintegrin and metalloproteinase 10 (ADAM10) 
which cleaves APP within the Aβ sequence, precluding Aβ formation. ADAM10 is 
localised to the plasma membrane, postsynaptic density and the trans-Golgi network 
(Lammich et al. 1999; Gutwein et al. 2003; Marcello et al. 2007). Activity-dependent 
synaptic plasticity regulates ADAM10 interaction with some of its binding partners which 
further regulates ADAM10 insertion into synaptic membranes (Musardo and Marcello 
2017). Enhancing ADAM10 and APP co-localisation within neurons might be beneficial 
since less APP would be cleaved by BACE1 and thereby less Aβ would be formed. 
Consequently, steering ADAM10 trafficking to cellular compartments where it may cleave 
APP might have potential as AD therapy.  
1.1.5 The amyloid cascade hypothesis 
A shift towards more amyloidogenic processing of APP and abnormal Aβ metabolism has 
been proposed to be the cause of AD. Although Aβ has physiological functions, e.g. as 
chelator and antioxidant, it appears to easily gain toxicity mainly by aggregating into 
oligomers (Atwood et al. 2003; Carrillo-Mora et al. 2014).  In 1991, Hardy and Allsop 
published the amyloid cascade hypothesis which states that excessive accumulation of Aβ 
initiates and drives the pathological changes in AD (Carrillo-Mora et al. 2014; Hardy and 
Allsop 1991; Hardy and Selkoe 2002).  
There is genetic support for the amyloid cascade hypothesis. The A673T mutation close to 
the β-secretase cleaving site of APP leads to a 40 % reduction in Aβ production and 
protects against AD (Jonsson et al. 2012) while all known genes causing FAD are related to 
APP or its processing, causing excessive Aβ production. In sporadic AD, on the other hand, 
the accumulation and aggregation of Aβ is considered a result of failure to effectively 
degrade and clear Aβ from the brain (Selkoe 2011; Selkoe and Hardy 2016).  
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Amyloid plaques are present in the brains of all AD patients. Transgenic animals with 
mutations in APP or the secretases involved in its processing, develop AD-like symptoms 
as well as several of the pathological hallmarks. This further supports the amyloid cascade 
hypothesis (Carrillo-Mora et al. 2014). Moreover, tau models with NFTs do not entirely 
mimic AD pathology (Hardy and Selkoe 2002).  
Yet, Aβ depositions are not specific to the brains of AD patients but may appear in subjects 
with other neurodegenerative diseases and even in cognitively normal and healthy elderly, 
making the amyloid cascade hypothesis debatable.  However, the amyloid plaques which 
are not associated with AD are diffuse and lack some of the characteristics of the amyloid 
plaques of AD patients, such as surrounding inflammation and glial activation (Hardy and 
Selkoe 2002; McLean et al. 1999; Näslund et al. 2000). 
1.1.6 Toxic effects of other APP-derived fragments 
There are indications that APP-CTFs are more toxic than previously believed and may be 
involved in the pathology of AD (Oster-Granite et al. 1996; McPhie et al. 1997; Kim et al. 
2003; Jiang et al. 2010; Lauritzen et al. 2012). Inhibition of γ-secretase causes a reduction in 
the number of dendritic spines in the brains of wild type but not APP knock-out mice, 
suggesting that accumulation of CTFs is likely to contribute to the adverse effects of γ-
secretase inhibition (Bittner et al. 2009). GSIs have been withdrawn from clinical trial due 
to lack of effect and increased cognitive decline was reported for some of the participants 
(Imbimbo and Giardina 2011). Deletion of the γ-secretase component presenilin leads to 
AD-like neurodegeneration (Saura et al. 2004). β-secretase inhibitors, but not γ-secretase 
inhibitors, can rescue synaptic and memory deficits in a model of familial Danish dementia 
(FDD) (Tamayev et al. 2012). Also phosphorylation of tau and over-activation of glycogen 
synthase kinase 3β (GSK3β), which is prominent in the AD brain, can be inhibited in 
induced pluripotent stem cells (iPSCs) by β-secretase inhibitors but not by γ-secretase 
inhibitors (Israel et al. 2012). In agreement with all this, CTF-β  is the first APP-derived 
fragment to accumulate in animal models of severe AD (Lauritzen et al. 2012).  
Other APP-derived fragments, such as caspase cleaved APP and an N-terminal fragment, 
have also been shown to be toxic (Galvan et al. 2002; Xu et al. 2015). Also CTF-η, the 
product of a newly identified, η-secretase processing of APP has been proposed to be toxic 
(Willem et al. 2015; Wang et al. 2015). CTF-η can be further processed by ADAM10 or 
BACE1 to generate the shorter fragments Aη-α and Aη-β. The levels of CTF-η and Aη are 
enriched in the brains of APP transgenic mice compared to wild type mice and in the 
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cerebrospinal fluid (CSF) from human AD patients where the levels of Aη exceed that of 
Aβ. Moreover, a 25 kDa CTF, probably identical to CTF-η, is more abundant in the CSF of 
AD patients and demented individuals with Downs syndrome than in control subjects 
(García-Ayllón et al. 2017). According to Willem et al. (2015) the proposed synaptotoxicity 
of Aβ dimers might actually be caused by Aη-α. When applied on hippocampal slice 
cultures, both synthetic Aη-α and Aη-α secreted from Chinese hamster ovary (CHO) cells 
caused a reduction in long term potentiation (LTP) ta a similar degree as synthetic Aβ 
dimers (Willem et al. 2015). In addition, inhibition of BACE1 leads to an increase in the 
levels of CTF-η and Aη-α at the same time as LTP is reduced (Willem et al. 2015). This 
should be taken into consideration when designing clinical trials with BACE1 inhibitors.  
1.1.7 Biomarkers and diagnosis  
Of all people living with dementia, only 20-50 % have been diagnosed in primary care 
(Winblad et al. 2016). Early and correct diagnosis is necessary in order to obtain support 
services and for the initiation of treatment available for symptomatic relief. Development of 
new, effective treatment also relies on early diagnosis since clinical trials seem to 
constantly fail when initiated at a stage when clinical symptoms of dementia are already too 
severe (Winblad et al. 2016). 
A combination of clinical and neuropathological examinations is used in the diagnosis of 
AD, which today can be diagnostically classified as “possible”, “probable” or “definite” 
AD. People with AD and people without dementia can be distinguished with fairly high 
specificity using the clinical diagnostic criteria of today. However, the distinction between 
AD and other dementias is less accurate. Therefore, combining clinical assessment with 
computed tomography (CT) scan, magnetic resonance imaging (MRI) and other biomarker 
assessments is generally used for diagnosis (Reitz and Mayeux 2014; Ballard et al. 2011).  
Different isoforms of Aβ as well as total and phosphorylated tau in the CSF are used as 
biomarkers for AD. Low levels of Aβ42 in the CSF and high levels of total tau and 
hyperphosphorylated tau distinguish AD patients from patients with other dementias. 
Combining different CSF biomarkers increases the specificity and sensitivity of the 
diagnosis (Hansson et al. 2006; Ballard et al. 2011). CSF biomarkers as well as imaging 
techniques are also used in research to predict conversion of MCI into AD. Markers of 
inflammation, oxidative stress and synaptic degeneration have potential as biomarkers and 
are currently being investigated (Ballard et al. 2011; El Kadmiri et al. 2017). Retrieving and 
analysing blood is less invasive, more cost effective and easier to perform in primary care 
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compared to CSF assessment. Consequently, blood biomarkers, e.g. different isoforms of 
Aβ in plasma, have high potential and are currently under investigation (Ballard et al. 2011; 
El Kadmiri et al. 2017). Unfortunately, blood biomarkers are still less specific and less 
accurate than are CSF biomarkers (El Kadmiri et al. 2017). 
Effective and reliable biomarkers as well as accurate diagnosis are essential in order to 
monitor and predict AD. In addition, biomarkers are of outmost value for assessment of the 
outcome when developing and testing disease modifying treatments.  
1.1.8 Risk and protective factors 
AD is a multi-factorial disease with no known direct cause. The main risk factor for AD is 
advanced age and the prevalence is increasing with age, being 1 % at the age of 65 and up 
to 50 % at the age of 85 (Prince et al. 2013). Dietary and life-style factors contribute to the 
progression of AD which shares many risk factors with cardiovascular disorders, such as 
smoking, hypertension, obesity, hypercholesterolemia and diabetes. Depression and 
traumatic brain injuries also increase the risk of developing AD (Reitz and Mayeux 2014; 
Rakesh et al. 2017). Advanced depression may cause brain atrophy, reduced levels of 
neurotrophins and increased inflammatory responses in the brain; symptoms which are 
common also in AD. Consequently, treating depressive disorders will also reduce the risk 
of developing AD and dementia, as will treatment of cardiovascular disorders and diabetes 
(Rakesh et al. 2017). Long-term treatment with e.g. non-steroidal anti-inflammatory drugs 
(NSAIDs), cholesterol-lowering drugs, oestrogen and vitamin E have been shown to reduce 
the risk of AD (Silvestrelli et al. 2006).  
Since higher education is associated with reduced risk of developing AD, cognitive reserve 
has been proposed to be protective (Stern 2012). Cognitive reserve refers to the brain’s 
capacity to use pre-existing cognitive processes and compensation mechanisms to 
circumvent pathology. Cognitive reserve would therefore increase with education as a 
result of the high brain activity and could in this way contribute to delay cognitive decline 
in AD (Stern 2012).  
Diet and lifestyle changes can greatly decrease the individual risk of developing AD by 
ameliorating the effect of the modifiable risk factors, such as those in common with 
cardiovascular disorders (Fig 3) (Reitz and Mayeux 2014; Rakesh et al. 2017). A 
Mediterranean diet reduces the risk of AD, proposedly since it to a large extent consists of 
plant-based food, olive oil and fish, which are high in essential nutrients and poly-
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unsaturated fat (Gu et al., 2010; Barnard et al., 2014). Increased physical activity is also 
beneficial and the amount of activity appears to be more important for the prevention of AD 
than the type of activity (Groot et al. 2016; Chu et al. 2015; Rakesh et al. 2017). Yet, the 
molecular mechanisms behind this effect remain unknown but increased vascularisation, 
improved plasticity and elevated levels of neurotrophins have been suggested (Rakesh et al. 
2017; Chu et al. 2015).  Even later life physical exercise may protect against AD and 
improve cognition. An 8-year longitudinal study showed that exercise of at least 30 minutes 
reduced the risk of cognitive decline regardless of physical or mental health and previous 
cognitive or social activity (Chu et al. 2015). In addition, physical activity can improve 
cognition for MCI patients (Nagamatsu et al. 2013; Groot et al. 2016). A large-scale long-
term randomised controlled trial demonstrated that multi-domain lifestyle changes, 
including restricted diet and a physical exercise training programme, have beneficial effects 
on cognition in relation to AD (Ngandu et al. 2015).  
 
Figure 3. Graphic summary of possible promising preventive strategies at different stages of the 
development of Alzheimer disease. Adapted from Rakesh et al., 2017. 
Genetic risk factors that increase the risk of developing AD have also been identified. 
APOE is the most common risk gene associated with sporadic AD and the gene product, 
apolipoprotein E, is a lipid-binding protein involved in cholesterol metabolism. The ε4 
allele of APOE greatly increases the risk of AD while the ε2 allele is associated with 
decreased risk (Raber et al. 2004). Genome-wide association studies have identified several 
other genes linked to an increased risk of AD, including complement receptor 1 (CR1), 
sortilin-related receptor 1 (SORL1), phosphatidyl-inositol binding clathrin assembly protein 
(PICALM) and clusterin (CLU) (Tosto and Reitz 2013). These risk genes can be clustered 
into four major pathways; 1) amyloid processing 2) inflammation, 3) lipid transport and 
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metabolism and 4) synaptic function/endocytosis (Tosto and Reitz 2013) emphasising the 
importance for these pathways in the development and progression of AD. 
1.1.9 Treatment 
Despite the fact that more than 100 years have passed since AD was first described, there 
still is no cure or treatment that effectively would stop the progression of the disease. Two 
classes of drugs are available but they only give symptomatic relief: choline esterase 
inhibitors and the N-methyl-D-aspartic acid (NMDA) receptor antagonist memantine 
(Silvestrelli et al. 2006).  
The cholinergic system is severely impaired in AD, contributing to memory decline and 
cognitive impairment. Choline esterase inhibitors supress the degradation of the 
neurotransmitter acetylcholine at the synaptic cleft, thus enabling more acetylcholine to 
activate the postsynaptic cell and maintain neurotransmission (Wenk 2006). Treatment with 
choline esterase inhibitors can increase the synaptic levels of acetylcholine but is unable to 
stop the progression of AD.  
Increased basal Ca2+ levels, in particular in glutamatergic neurons, are common in AD. The 
mechanisms are not clear but possibly involve dysfunctional mitochondria at synapses as 
well as increased Ca2+ entry through NMDA receptors (Wenk 2006). Memantine maintains 
normal neurotransmission by blocking extrasynaptic NMDA receptors which reduces 
excitotoxicity and excessive glutamate signalling. Memantine is a low-moderate affinity 
NMDA receptor antagonist with fast on/off kinetics which is crucial for its ability to inhibit 
excessive NMDA receptor stimulation while allowing normal, physiological neuro-
transmission (Silvestrelli et al. 2006; Wenk 2006).  
Reducing the levels of Aβ in the brain is a major treatment strategy where there currently is 
much focus. γ- and β-secretase inhibitors and GSMs which cause a reduction in Aβ 
production, have been in clinical trials, so far without success (Mikulca et al. 2014; 
Bachurin et al. 2017; Kandalepas and Vassar 2014). A phase I clinical trial of the BACE 
inhibitor verubecestat or MK-8931 markedly reduced the levels Aβ in the CSF (Winblad et 
al. 2016). Results from a phase III clinical trial in prodromal AD and MCI are expected in 
2019. However, another phase III clinical trial with the same drug on mild to moderate AD 
patients had to be prematurely withdrawn due to lack of effect (Alzforum). As mentioned in 
section 1.1.4, no success has been achieved with GSIs or GSMs. Drugs targeting γ-
secretase are rather associated with toxicity and adverse effects, probably due to 
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accumulation of other, toxic APP-derived fragments, off-target effects and dosage 
(Bachurin et al. 2017; Winblad et al. 2016).  
Specifically reducing Aβ toxicity by destabilising or neutralizing oligomeric Aβ is a 
promising approach, however no major break-through has been made so far. Active and 
passive immunisation against Aβ has proven efficacious in animal models although not yet 
in humans (Silvestrelli et al. 2006; Wang et al. 2017; St-Amour et al. 2016). A phase II 
clinical trial of the AN1792 vaccine against Aβ42 had to be terminated due to the 
development of aseptic meningoencephalitis in 6 % of the participants. Yet immune-
responding patients also showed reduced levels of Aβ in the brain and, importantly, a slight 
decline in the rate of cognitive impairment, emphasising the potential of the approach 
(Gilman et al. 2005; Masliah et al. 2005). Immunisation using modified antigens, such as 
truncated Aβ, which cause less immunological responses, is currently in clinical trials (St-
Amour et al. 2016). BIIB37, or aducanumab, is a monoclonal antibody against a 
conformational epitope of Aβ. Positive, dose-dependent effects with improved cognition 
have been reported from a large phase I clinical trial and aducanumab will now proceed 
directly into phase III (Biogen web page; Sevigny et al., 2016). Anti-tau vaccines have also 
been developed and some are in clinical trials (St-Amour et al. 2016). Stimulating 
regeneration to increase neurogenesis is a rather new and promising approach (Felsenstein 
et al. 2014). 
In the Dominantly Inherited Alzheimer Network (DIAN) individuals with FAD are 
registered and studied. Pathological changes in the brain of these individuals often arise 
long before clinical symptoms (Winblad et al. 2016). The DIAN Trials Unit (TU) is a 
preventive trial with drugs targeting Aβ (immunisation and BACE inhibitor) to evaluate 
drug safety, tolerability and effectiveness. The main aim is to delay, prevent or even reverse 
the pathological changes and clinical symptoms of AD (clinicaltrials.gov). 
Discovering reliable biomarkers for early diagnosis is urgently needed for the treatment of 
AD. Identifying preclinical stages of sporadic AD would enable design of clinical trials 
aiming at preventing the onset of dementia by reversing synaptic and neuronal dysfunction. 
For effective disease modifying treatment early initiation is necessary. 
1.2 SYNAPTIC FUNCTION  
Synapses are highly specialised structures at which neurons communicate. Remodelling of 
synaptic connections in the brain is a prerequisite for memory formation and enables us to 
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interact with the world around us. Synaptic dysfunction and loss of synapses, on the other 
hand, may impair brain network activity.  
Simultaneous activity in nearby synapses leads to LTP which persistently strengthens and 
sensitizes the synapses for further stimulation. In a similar fashion does asynchronous 
stimulation decrease synaptic strength by causing long-term depression (LTD) (Kandel et al 
2014). NMDA receptors play a pivotal role in synaptic plasticity. Depending on the amount 
of Ca2+ influx through these receptors and the subsequent signalling cascades activated at 
the dendrites, either LTP or LTD is induced (Kullmann and Lamsa 2007). LTP induces 
increased insertion of α-amino-3-hydroxy-5-methyl-4-isoxazolepropionic acid (AMPA) 
receptors to the postsynaptic membrane and growth of dendritic spines whereas synapse 
loss and spine shrinkage is associated with LTD (Kullmann and Lamsa 2007).  Impaired 
synaptic plasticity is often detrimental and can lead to cognitive decline and memory 
dysfunction, as is the case in AD (Spires-Jones and Hyman 2014). 
1.2.1 Synaptic alterations in Alzheimer disease 
The number of synapses in the brain decrease during normal aging, not only as a 
consequence of neurodegeneration.  However, the synapse-to-neuron ratio is significantly 
lower in the brains of AD patients compared to elderly persons without AD, especially at 
brain areas particularly affected by AD. For example, at the hippocampus of AD patients 
the synapse-to-neuron ratio is up to 50 % lower than the ratio in the same area of non-
demented elderly and adults (Bertoni-Freddari et al. 1990). At the cortex of AD patients 
there are 25-30 % less synapses than at the cortex of persons without AD and 15-35 % 
fewer synapses per cortical neuron (DeKosky and Scheff 1990; DeKosky et al. 1996; Davies 
et al. 1987). In line with this, the levels of both pre- and postsynaptic proteins are lower in 
AD patients compared to age-matched control subjects (Reddy et al., 2005). Accordingly, 
synaptic loss correlates better with cognitive decline than amyloid plaques, NFTs or 
neuronal loss (Terry et al. 1991; DeKosky and Scheff 1990). 
1.2.2 Aβ at the synapse 
Soluble forms of intracellular Aβ interfere with synaptic function and contribute to the loss 
of synapses and synaptic proteins (Selkoe 2008; Bayer and Wirths 2010; Musardo and 
Marcello 2017). Aβ co-localise with postsynaptic density-95 (PSD-95) protein in AD brain 
(Lacor et al., 2004) and the levels of PSD-95 are decreased in the brains of AD patients in 
an Aβ dependent manner, correlating with the severity of dementia (Gylys et al. 2004). 
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Spine loss and reduced levels of AMPA receptors at the synaptic membrane is observed in 
parallel to the decreased PSD-95 levels (Gylys et al. 2004).  
Aβ oligomers are present both pre- and postsynaptically, particularly in synapses 
surrounding amyloid plaques (Koffie et al. 2012; Pickett et al. 2016; Koffie et al. 2009) and 
impair synaptic structure and function both in vitro and in vivo (Hsia et al. 1999; Kamenetz 
et al. 2003; Mucke et al. 2000; Shankar et al. 2008; Walsh et al. 2002; Koffie et al. 2009). 
Aβ oligomers may activate caspases and calcineurin and thereby cause Ca2+ dys-
homeostasis (Abdul et al. 2009; Kuchibhotla et al. 2008). Moreover, Aβ disturbs excitatory 
synaptic transmission, particularly by affecting AMPA and NMDA and receptor endo-
cytosis and thus the availability of these receptors at the synapse (Musardo and Marcello 
2017; Shankar et al. 2008; Hsieh et al. 2006; Li et al. 2009). Through these actions, 
oligomeric Aβ inhibits LTP and facilitates the induction of LTD (Koffie et al. 2011; 
Musardo and Marcello 2017).  
Oligomeric forms of Aβ may also affect neuronal glutamate reuptake (Li et al. 2009) and 
cause an increase in glutamate release from astrocytes (Talantova et al. 2013). The excess 
of glutamate around the synapses may then activate extrasynaptic NMDA receptors which 
may cause excitotoxicity (Talantova et al. 2013). 
Learning is disrupted in rats after injection of naturally secreted human soluble oligomeric 
Aβ (Cleary et al. 2005) and soluble oligomeric Aβ impairs synaptic plasticity also in 
neuronal cultures (Townsend et al. 2006). Oligomeric Aβ may induce cognitive deficits 
before amyloid plaque formation in APP transgenic mice (Westerman et al. 2002; 
Koistinaho et al. 2001).  
Neurons of the AD affected brain appear to be presynaptically hyperactive and neuronal 
activity is impaired in AD, both at the level of network circuits and at individual synapses 
(Palop and Mucke 2010; Palop et al. 2007). Increased synaptic activity cause an increase in 
extracellular and decrease in intracellular Aβ levels (Cirrito et al. 2005; Kamenetz et al. 
2003; Tampellini et al. 2009). Aβ may enter cells through membrane permeabilisation 
(Kayed et al. 2009) and endocytosis (Nath et al. 2012) but the mechanism by which Aβ is 
secreted is still unknown.  
To prevent further synapse loss, inhibit excitotoxicity or even facilitate synaptogenesis, 
removal of oligomeric Aβ from synapses is an attractive approach. However, no anti-
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amyloid immunotherapeutic studies aiming at clearing Aβ from the brain has yet been 
successful (Montoliu-Gaya and Villegas 2016). 
 
  
  17 
2 AIMS 
The main aim of this thesis was to investigate the secretion mechanisms of Aβ as well as 
the subcellular localisation of its precursor and the enzymes involved in its production at 
the synapse. 
The specific aims of the individual papers were: 
 
PAPER I: Activity-independent release of the amyloid-β 
peptide from rat brain nerve terminals 
To test the hypothesis “Aβ is produced and stored in synaptic vesicles and released together 
with neurotransmitters during synaptic stimulation”. 
 
PAPER II: ADAM10 and BACE1 are localized to synaptic 
vesicles 
To investigate the synaptic localisation of the APP processing enzymes. 
 
PAPER III: Similar pre- and postsynaptic distribution of 
ADAM10 and BACE1 in rat and human adult brain 
To investigate the in situ synaptic localisation of APP and the APP processing enzymes in rat 
and human adult brain. 
 
PAPER IV: A 25 kilodalton amyloid precursor protein C-
terminal fragment is abundant in human but not in mouse 
or rat brain 
To investigate the levels of 25 kDa CTF as well as other APP-derived fragments in human 
AD and control brain and in the brains of other animals. 
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Figure 4. A synaptosome with a 
synaptic vesicle-filled presynpastic 
terminal, synaptic cleft and dense 
postsynaptic density. The presynaptic 
terminal also contain mitochondria. 
3 METHODOLOGICAL CONSIDERATIONS 
3.1 ETHICAL CONSIDERATIONS 
All studies in this thesis involving humans and other animals were performed in accordance 
with the declaration of Helsinki, the current European Law (Directive 2010/63/EU) as well 
as the local ethical review board and the guidelines at Karolinska Institutet or the guidelines 
at the university or facility where the animals were kept or the experiments conducted. The 
human post mortem brain tissue used in paper III was obtained from the Harvard Brain 
Tissue Resource Center at the NIH Brain Bank, US, while the human brain material used in 
paper IV was obtained from the Brains for Dementia Research, London, UK, and the Brain 
Bank at Karolinska Institutet, Stockholm, Sweden. 
3.2  PREPARATION OF SYNAPTOSOMES 
In order to study synaptic mechanisms without 
involvement of cell body events, synaptosomes were 
isolated from rat brain.  Synaptosomes are pinched off 
and resealed nerve endings which, in case they are 
prepared from fresh brain tissue, are functional and 
may be stimulated to release neurotransmitters (Fig 4). 
Therefore synaptosomes have been extensively used 
to study the regulation of neurotransmitter release as 
well as other synaptic events under different 
conditions. 
Synaptosomes were prepared essentially as described before by Nicholls (1978). In brief, 
cerebellum and cortex of five weeks old Wister rats were homogenised in sucrose buffer 
using a pestle homogeniser. Nuclei and cell debris were first spun down. The subsequent 
supernatant was further centrifuged to collect synaptosomes, mitochondria and other 
membrane organelles in the pellet which was resuspended in sucrose buffer, layered on a 
discontinuous ficoll gradient (6-9-13 %) and centrifuged at 62 500 x g for 35 min at 4 ºC. 
The fraction containing synaptosomes was collected from the 9-13 % ficoll interface and 
centrifuged at 9 500 x g for 12 min at 4 ºC. The synaptosomes were then resuspended in 
sucrose buffer. 
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3.3 SYNAPTOSOMAL STIMULATION AND GLUTAMATE RELEASE ASSAY  
KCl and 4-aminopyridine (4-AP) are widely used to experimentally induce action potentials 
and synaptic activity. 4-AP blocks voltage-gated potassium channels, thereby inhibiting 
potassium efflux which normally stabilises the membrane potential after the initial 
depolarisation caused by sodium influx. When potassium cannot leave the depolarised 
axon, the synapses remain active. Addition of KCl to a synaptosomal solution would 
increase the extrasynaptosomal potassium levels thus decreasing the concentration gradient 
of potassium between the (normally high potassium) cytosol and the (normally low 
potassium) extracellular environment. Potassium would not leave the synaptosomes against 
its chemical gradient, thus leaving the synapses continually active. 
KCl- and 4-AP-induced glutamate release was measured by the conversion of NADP to 
NADPH by glutamate dehydrogenase. In the presence of water and NADP, glutamate 
dehydrogenase converts glutamate into α-ketoglutarate while NH4+ and NADPH are 
produced as by-products (Fig 5). Since NADPH is fluorescent and its levels directly 
correspond to the levels of glutamate in the solution, increased fluorescence in response to 
KCl or 4-AP directly correlates to glutamate release.  
 
Figure 5. The reversible enzymatic reaction catalysed by glutamate dehydrogenase.  
Synaptosomes were spun down and resuspended in sodium buffer containing protease 
inhibitors and subsequently placed in a fluorometer at 37 ºC. The synaptosomal solution 
was allowed to reach the correct temperature by incubation for 3 min. CaCl2 or EDTA (a 
calcium chelator used as negative control) and NADP was subsequently added. After 1.5 
min incubation glutamate dehydrogenase was added and the fluorescence measurement 
started. After another 5 min the fluorescence level had stabilised since the enzymatic 
reaction had had time to reach equilibrium, and KCl or 4-AP was added to a final 
concentration of 50 mM and 1 mM, respectively. The measurement continued for another 6 
min. 
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In figure 6, glutamate release in response to KCl (a) and 4-AP (b) is presented as an 
increase in fluorescence when NADP is converted into NADPH in the presence of KCl or 
4-AP. As EDTA is a calcium chelator, and calcium is necessary for SV exocytosis and thus 
neurotransmitter release, less glutamate is released in the presence of EDTA than CaCl2. 
However, to our surprise, 4-AP was much less effective in inducing synaptic glutamate 
release (and thus synaptic activity) than KCl (Fig 6).  
 
Figure 6. Glutamate release from synaptosomes in response to stimulation by KCl or 4-AP. 
Representative figures of glutamate release as assessed by conversion of NADP to fluorescent NADPH by 
glutamate dehydrogenase. 50 mM of KCl (a) or 1 mM 4-AP (b) was added at the indicated time-point. 
Fluorescence was measured in the presence (blue line for KCl and purple line for 4-AP) or absence (red line) 
of Ca2+. NRC (non-reaction control, green line) denotes non-stimulated synaptosomes. Numbers denote 
relative fluorescence units (RFU). (From Lundgren et al., 2014) 
3.4 ENZYMATIC ACTIVITY ASSAYS 
To determine ADAM10 enzymatic activity in brain homogenates and SVs, we used the 
commercial SensoLyte® 520 ADAM10 Activity Assay Kit which is based on the FRET 
substrate 5-FAM/QXLTM 520 with excitation/emission of 490/520 nm. The required 
reagents were provided in the kit and the manufacturer’s protocol was followed. 
Homogenate or SVs were resuspended in reaction buffer in the presence or absence of the 
matrix metalloproteinase inhibitor GM-6001 and placed in a black 96 well plate. The 
enzymatic reaction was started by addition of substrate and fluorescence was measured 
every 5 min for 60 min at 37 °C at an excitation/emission of 485/520 nm. 
3.5 PROXIMITY LIGATION ASSAY 
Proximity ligation assay (PLA) is a sensitive method for in situ detection of proteins which 
are in close proximity to each other. It is superior to most other co-localisation methods as 
it only requires a distance of maximum 40 nm between the two labelled proteins in order to 
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give rise to a signal. Two proteins are labelled, first with primary antibodies and then with 
secondary oligonucleotide probes directed toward the primary antibodies. If the two 
proteins are in sufficiently close proximity (≤40 nm), the secondary oligonucleotide probes 
can be ligated, amplified and subsequently detected as a PLA-signal visualised by either a 
fluorescent or light microscope, depending on the PLA kit used (Fig 7) (Söderberg et al. 
2008). As negative controls we either used only one of the primary antibodies or omitted 
primary antibodies altogether.  
 
Figure 7. The proximity ligation assay method. The proteins of interest are labelled with primary antibodies 
which are recognised by secondary, oligonucleotide-labelled probes. If these probes are in less than 40 nm 
proximity, the oligonucleotides may be ligated and amplified by a rolling circle amplification mechanism and 
fused to fluorescently-labelled complementary nucleotides. Where the two proteins are in close proximity, 
fluorescent dots are detected by confocal microscopy. For brightfield PLA, detection and substrate solutions 
are also needed for production of signals visible by light microscope. (Amplified Detection, Duolink® 
Proximity Ligation Assay (PLA), Merck, Sigma) 
In the present thesis fluorescent PLA was used in paper II to investigate the proximity of 
ADAM10, BACE1 and a probe for active γ-secretase with the SV protein synaptophysin in 
mouse primary hippocampal neurons. In paper III, we used PSD-95 in addition to 
synaptophysin, in order to also detect postsynaptic localisation of the secretases. In that 
paper we applied brightfield PLA since human brain often is auto-fluorescent which may 
interfere with the detection of fluorescent PLA signals. 
An SV is about 40 nm in diameter and there are approximately 32 copies of synaptophysin 
per vesicle (Takamori et al. 2006). Thus, since all labelled proteins within 40 nm distance 
give rise to PLA signals, all proteins in an individual SV should give rise to PLA signals 
when labelled together with synaptophysin. This makes PLA a very sensitive method for 
co-localisation studies. However, we have found that it is challenging to quantify the results 
since PLA is not always very reproducible and large inter-experimental differences are 
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common. Careful sample preparation and handling seem to be extremely important and it is 
necessary to ensure the whole tissue section is covered during all incubation steps, 
especially during incubations at 37 ºC when the solutions may evaporate. Consequently, 
small variances might affect the results as PLA is such a sensitive method. 
3.6 ACCELL siRNA 
Cortical neurons isolated from 16 days old mouse embryos were seeded on poly-D-lysine 
coated 24 well plates. At 4 days in vitro (DIV) half of the Neurobasal media was exchanged 
to BrainPhys media and 1.5 mM Accell SMARTPool siRNA (APP or scrambled, non-
coding control siRNA) was added. Half of the media was replaced by new BrainPhys media 
at 8 DIV. At 14 DIV, Alamar Blue cell viability assay was performed to ensure that the 
neurons were healthy and metabolically active. Thereafter the neurons were washed and 
lysed in Benzonase buffer.  
Using this technique we have managed to very efficiently abolish the expression of some 
genes in our primary neuronal cultures. However, we have experienced large difficulties in 
silencing the expression of some other genes. Consequently, we are currently trying to better 
manage this technique. Yet, we suspect that our unsuccessful experiments are mainly results 
of varying efficiency of the different siRNAs.   
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4 RESULTS AND DISCUSSION 
4.1 GLUTAMATE AND Aβ ARE RELEASED FROM SYNAPSES THROUGH 
DIFFERENT MECHANISMS 
Aβ is continuously secreted from neurons (Moghekar et al. 2011) and increased synaptic 
activity cause an increase in Aβ release both in vitro and in vivo (Lazarov et al. 2002; 
Kamenetz et al. 2003; Cirrito et al. 2005; Cirrito et al. 2008). In addition, Wei et al. (2010) 
have demonstrated that Aβ released from both pre- and postsynaptic compartments can 
have local neurotoxic effects on dendritic spines and synaptic function. Our group and 
others have shown that Aβ can be produced at the synapse and that the SVs contain all 
components needed for Aβ production (Frykman et al. 2010; Groemer et al. 2011). In paper 
I we show that Aβ can be produced in pure SVs and hypothesised that it would be released 
from synapses through normal SV exocytosis during synaptic activity. We used KCl and 4-
AP to induce synaptic activity in synaptosomes and subsequently measured the levels of 
glutamate and Aβ released into the extracellular solution. Contrary to what we expected, we 
found that Aβ secretion was not affected by synaptic stimulation, but that there was 
considerable activity-independent release of Aβ from synaptosomes kept at 37 ºC. 
Glutamate release, on the other hand, was highly dependent on synaptic activity (Fig 6).  
In conclusion, we demonstrated that small amounts of Aβ can be produced in SVs but that 
Aβ is not released from nerve terminals through normal SV exocytosis. Consequently, the 
release mechanisms of Aβ and glutamate are different.  
Contrary to our findings, Kim et al. (2010) observed a time-dependent increase in Aβ 
secretion from KCl-stimulated synaptosomes at 25 ºC. However, they had not included a 
negative control of unstimulated synaptosomes, thus it is not possible to know if the 
increase in Aβ release actually was activity-dependent. 
By using synaptosomes, we were able to study the effect of synaptic activity on Aβ release 
without involvement of cell body events such as translation and trafficking of proteins. 
Dolev et al. (2013) demonstrated that presynaptic events (electrically induced spike bursts) 
affect the conformation of presenilin at the postsynaptic membrane, consequently 
increasing Aβ40 secretion and the extracellular Aβ40/42 ratio. Single spikes caused release 
of equal amounts of Aβ40 and Aβ42. However, in our system the secretion of both Aβ40 
and Aβ42 was continuous and activity-independent, indicating that the effects observed by 
Dolev et al. (2013) were dependent on intact cells and possibly even on larger neuronal 
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circuits. Yet, we use other techniques than Dolev et al. (2013) to induce synaptic activity 
and this could possibly affect the results. 
However, it is still also possible that the activity-dependent release of Aβ is dependent on 
intact postsynaptic compartments and/or entire dendritic spines. Delivering pre- or 
postsynaptically targeted APP to rodent primary hippocampal neurons by lentiviral 
transduction, DeBoer et al. (2014) found that more Aβ is released into the conditioned 
media from dendrites than from axons. Moreover, by two-photon microscopy of 
organotypic rat hippocampal slice cultures, Wei et al. (2010) demonstrated that spine 
density is decreased in the vicinity of both dendrites and axons of APP overexpressing 
neurons. This effect was absent in the presence of the γ-secretase inhibitor L685,458 
indicating that it was Aβ dependent. Similarly, Wei et al. (2010) further demonstrated that 
Aβ released from both dendrites and axons also caused impairments of other synaptic 
functions. These findings support the notion that the activity-dependent release of Aβ 
might, at least in part, be of postsynaptic origin. Yet, more studies are needed to also clarify 
the role of protein trafficking and other cell body dependent mechanisms in the activity-
dependent release of Aβ. 
4.2 SYNAPTIC DISTRIBUTION OF ADAM10 AND BACE1 
Aβ levels are affected by protein trafficking and the subcellular localisation of different 
proteins, especially the enzymes involved in its production (Haass et al. 2012). Genome-
wide association studies put emphasis on the importance of protein trafficking in the 
pathology of AD. Many AD patients carry genetic variances in genes coding for several 
proteins involved in trafficking and endocytosis (Tosto and Reitz 2013). Because of the 
synaptotoxicity of Aβ and the known synaptic dysfunction and degeneration in AD, 
targeting trafficking of APP producing proteins could be an attractive therapeutic approach. 
This, however, requires careful understanding of how the trafficking is regulated, as well as 
knowledge of the precise cellular location of the APP processing enzymes. 
Performing more Western blotting of the SVs from my first project, we found that both 
ADAM10 and BACE1, but only presenilin of the components of the γ-secretase complex, 
were highly enriched in SVs compared to total rat brain homogenate (Fig 8). Likewise, 
CTF-α and -β, the products of ADAM10 and BACE1 cleavage of APP, were also highly 
enriched (Fig 8). BACE1 has long been known to localise to the presynaptic compartment 
and Del Prete et al. (2014) have found this enzyme also in SVs. However, we use a different 
protocol for SV purification and found more enrichment of BACE1 in our highly pure SVs 
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Figure 8. Western blot of rat brain homo-
genate and synaptic vesicles. ADAM10, 
BACE1 and the C-terminal fragments (APP-
CTFs) are highly enriched in synaptic vesicle 
fractions (SV) compared to total brain 
homogenate (H). 
compared to total brain homogenate than Del 
Prete et al.  Moreover, in contrast to Del Prete et 
al., we also detected enrichment of the CTFs in 
SVs, indicating that ADAM10 and BACE1 are 
also active in the SVs. Indeed, we were able to 
show ADAM10 activity in SVs using an in vitro 
enzymatic activity assay although we did not 
succeed in detecting BACE1 activity. Yet, the 
enrichment of both the enzyme and cleavage 
product suggests that BACE1 is also active in 
SVs. The assays available are probably not 
optimal for biological samples since most BACE1 
assays are based on recombinant protein as well as 
on synthetic substrates and were originally 
designed for compound screening. In spite of this, other groups have previously been able 
to measure BACE1 activity in human brain homogenate (Fukumoto et al. 2002; Li et al. 
2004). Another option, though unlikely, is that the CTFs that are enriched in the SVs have 
been transported there from elsewhere. 
Using PLA, we further demonstrated that a large amount of both ADAM10 and BACE1 
was in close proximity to the SV protein synaptophysin in mouse embryonic primary 
hippocampal neurons. This was a new and interesting finding, since to our knowledge 
ADAM10 had not previously been reported to localise to the presynapse. In addition, since 
PLA of active γ-secretase and synaptophysin only gave rise to a few PLA signals, these 
results indicate that the secretases are present at different presynaptic locations, which 
might be a limiting factor for synaptic Aβ production. The CTFs produced in SVs might 
thus be trafficked to other synaptic compartment(s) for γ-secretase cleavage and Aβ 
production. Recycling endosomes, autophagic vesicles and exosomes have been reported to 
be involved in Aβ secretion (Rajendran et al. 2006; Nilsson et al. 2013; Udayar et al. 2013) 
and are therefore likely γ-secretase containing compartments where Aβ production could 
take place.  
By using confocal microscopy and PLA of mouse primary neurons, Nigam et al. (2015) 
observed that much less C-terminally labelled APP co-localised with presynaptic proteins 
than did N-terminally labelled APP. However, in neurons from BACE1 knock-out mice, C-
terminally labelled APP was increased presynaptically due to more full length (FL)-APP 
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(N-terminally labelled APP) being present (and probably processed) there. This could be 
considered contradictory to our findings of enrichment of CTFs in SVs. However, also 
AICD, generated by γ-secretase cleavage of CTFs, would be labelled with the APP C-
terminal antibodies used by Nigam et al. The AICD functions as a transcription factor and 
is thus translocated to the nucleus directly after it is produced (Multhaup et al. 2015). 
Therefore, it could be assumed that the synaptic levels of AICD would be low. 
Consequently, APP C-terminal antibodies would strongly label perinuclear AICD during 
confocal imaging which could have a neutralising effect on the enrichment of CTFs we 
observe in SVs by Western blotting. We also show that the levels of FL-APP are somewhat 
enriched in SVs compared to total brain homogenate, although not to the same extent as the 
CTFs. However, this does not necessarily mean that there are more copies of CTFs than 
APP in SVs as the total amount of cellular APP probably exceeds the total cellular amount 
of CTFs. Regardless, it would be interesting to analyse the levels of the different APP-
derived fragments in SVs isolated from BACE1 knock out animals as well as to perform the 
same set of PLA experiments on primary neurons or brain slices from these animals. 
The findings of Nigam et al. (2015) are supported by those of DeBoer et al. (2014) who 
used lentiviral transduction of rodent primary neuronal cultures to demonstrate that surface 
FL-APP is primarily localised to axons while intracellular FL-APP as well as C-terminally 
labelled APP is more equally distributed between axons and dendrites. Thus, using confocal 
microscopy as performed by Nigam et al. (2015), it is quite evident that FL-APP would 
appear to co-localise more with presynaptic proteins than would C-terminally labelled APP. 
Yet, considering the great enrichment of CTFs in SVs, it reasonable to assume that the 
majority of presynaptic, axonal CTFs could reside in SVs, supporting our results. 
Following up on these findings, in paper III we further investigated the synaptic distribution 
of ADAM10 and BACE1 as well as their substrate APP. Again PLA was used, but this time 
in sections of rat and human adult brain. In addition to synaptophysin, we also performed 
PLA of the secretases together with the postsynaptic protein PSD-95. We confirmed that 
both ADAM10 and BACE1 were present presynaptically and could demonstrate that they 
were both also found postsynaptically (Fig 9). Likewise, APP was also in close proximity 
to both synaptophysin and PSD-95, as well as to both ADAM10 and BACE1. We also 
confirmed the pre- and postsynaptic localisation of both ADAM10 and BACE1 by Western 
blotting of SV and PSD fractions from rat brain. 
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Figure 9. Proximity ligation assay of human AD brain. Human AD brain sections were subjected to PLA 
using antibodies toward ADAM10 or BACE1 and the presynaptic marker synaptophysin or the postsynaptic 
marker PSD-95. Both ADAM10 and BACE1 are localised both pre- and postsynaptically. Scale bar 20 µm. 
PLA gives rise to signals if the two labelled proteins are within 40 nm distance from each 
other. Consequently, one drawback of using PLA when studying synaptic proteins is that 
the synaptic cleft is only approximately 20 nm. Thus, it is possible that labelled presynaptic 
proteins could give rise to PLA signals together with PSD-95, and that labelled post-
synaptic proteins likewise could give rise to PLA signals together with synaptophysin. 
However, given the amount of signals generated in our experiments, we find it highly 
unlikely that such false positive signals would have an impact on our conclusions. In 
addition, we also confirmed our PLA results using subcellular fractionations both in Paper 
II and III. 
Our results are further supported by the fact that both pre- and postsynaptically residing 
proteins have been identified as substrates for both ADAM10 and BACE1 (Munro et al. 
2016; Zhu et al. 2016; Kuhn et al. 2016). Accordingly, our co-author Marcello et al. (2007) 
have previously shown enrichment of not only ADAM10, but also BACE1 in PSD fractions 
purified from mouse brain. Thus, we consider that the localisation of ADAM10 and 
BACE1 both pre- and postsynaptically has physiological relevance. Nevertheless, we were 
unfortunately unable to quantify potential differences between control and AD cases due to 
inter-experimental variations. 
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Figure 10. Pattern of APP-derived fragments in 
human and rat brain homogenate. Western blot 
of C99-flag (synthetic CTF-β) and human and rat 
brain homogenates. The Y188 and C1/6.1 anti-
bodies recognising the C-terminal part of APP 
were used for detection. The molecular marker 
does not migrate correctly as C99 has a molecular 
weight of 12 kDa. The 25 kDa CTF is abundant in 
human brain but not in rat brain. 
4.3 A 25 kDa C-TERMINAL FRAGMENT IS THE MOST ABUNDANT APP-CTF 
IN HUMAN BRAIN 
When working with the first papers of this thesis, we used the Y188 APP antibody for 
Western blotting and repeatedly found a 25 kDa CTF to be the most abundant APP-derived 
fragment in human brain. This CTF was hardly detectable in rat and mouse brain. It has 
been shown that not only Aβ, but also APP-CTFs and AICD can exert neurotoxic effects 
(Passer et al., 2000; Kim et al. 2003; Saura et al., 2004; Bittner et al., 2009; Jiang et al., 
2010; Lauritzen et al., 2012), emphasising the importance of careful elucidation of APP 
processing and the different fragments produced thereof. In addition, both Wang et al. 
(2015) and Willem et al. (2015) had fairly recently discovered an APP-CTF, CTF-η, that 
migrates around 25 kDa on an SDS-PAGE gel. Hence, we considered it important to further 
study the pattern of APP-derived fragments in the brains of humans and other animals. 
Using five different APP antibodies, we 
consistently found this 25 kDa CTF to be 
abundant in human brain homogenate, but 
present at much lower levels in rat brain 
homogenate (Fig 10). Yet, the ratio between 
this and other CTFs varied in human brain 
depending on which antibody we used for 
detection. Differences in epitope exposure 
and/or antibody affinity are probable 
reasons for this discrepancy. Other groups 
have previously shown that APP-derived 
fragments migrating between 20 and 30 kDa 
on SDS-PAGE gels are present in human 
brain (Haass et al. 1992; Tamaoka et al. 
1992; Estus et al. 1992) although they have 
not thoroughly characterised or identified 
these fragments. However, we have found that different molecular markers do not migrate 
consistently on SDS-PAGE gels and different gel systems might also give rise to somewhat 
different protein patterns during Western blotting. Therefore it is likely that at least some of 
these CTFs are in fact identical to CTF-η and/or the 25 kDa CTF detected by us. Further-
more, when using 16 % tricine gels, which efficiently separate proteins of low molecular 
weight, we found that the 25 kDa CTF could actually be distinguished as two bands on the 
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blots. This is in agreement with Wang et al. (2015) who observed that CTF-η is detected as 
“a cluster of two or more fragments close in size”. 
Even though we did not manage to immunoprecipitate the 25 kDa CTF from human brain 
homogenate, a strong indication of it being a true APP-derived fragment is the fact that it is 
absent in the lysates of APP siRNA treated mouse embryonic primary neurons. The 25 kDa 
CTF was hardly detectable in mouse brain homogenate. However, when loading human 
brain homogenate and mouse embryonic primary neurons on the same gel, we detected a 25 
kDa CTF in untreated and scrambled treated mouse embryonic neurons migrating at the 
same position as the human 25 kDa CTF. Yet, the murine 25 kDa CTF was present at much 
lower levels. Accordingly, Willem et al. (2015) detected CTF-η in both adult and postnatal 
day 10 wild type mouse brain. 
To further characterise the 25 kDa CTF, we examined its expression pattern in different 
species and found that it was present in human, guinea pig and macaque brain. At the same 
time, using the C1/6.1 antibody, a fragment migrating just above the 25 kDa CTF was 
detected in rat, mouse and, to some extent in guinea pig brain but not in human or macaque 
brain. Whether this band is the same CTF with other and/or more post-translational 
modifications or unspecific binding of the antibody to the membrane was unclear. 
Alternatively, the exact cleavage site could be different in different species or this could be 
yet another APP-derived fragment. In any case, the 25 kDa CTF was not present in the 
brains of transgenic mice expressing human APP with the Swedish/London mutation. This 
implies that it is not the human sequence of APP that determines the production of this 
fragment, but rather the environment in the human brain. However, production of the 25 
kDa CTF in the brains of these transgenic mice might be competed out by the increased β-
cleavage caused by the Swedish mutation of APP. However, although more β-cleavage of 
APP takes place in the brains of these transgenic mice, they also greatly overexpress APP 
(Westerman et al. 2002; Kawarabayashi et al. 2001) and therefore one could assume that 
there would be some production the 25 kDa CTF also in these mice if they had all 
component needed for the process. 
Investigating the 25 kDa CTF in human CSF, García-Ayllón et al. (2017) observed 
increased levels of this fragment in both familial and sporadic AD patients as well as in 
aged Down syndrome individuals as compared to control CSF. However, when quantifying 
the 25 kDa CTF from Western blots of ten sporadic AD and ten control brain homogenates 
we were not able to detect any significant differences. Neither were there any apparent 
differences in the levels of this fragment between the familial AD and control brains we 
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analysed. Yet, we observed large inter-individual differences. Since CTFs are membrane-
bound proteins, a general degradation of membranes in AD brain would therefore 
presumably release more CTFs into the CSF, whereas the CTF levels in the brain would 
more closely correlate to the total brain protein content. This could possibly explain why 
we, contrary to García-Ayllón et al. (2017), could not detect any differences in the brain 
levels of the 25 kDa CTF between AD and control subjects.  
Altogether, these data reveal that a 25 kDa CTF is among the most abundant APP-derived 
fragments in human brain but not in rat and mouse brain. It is necessary to take the species 
difference into consideration when designing clinical trials based on previous animal 
experiments. Moreover, these differences may be a possible explanation as to why humans, 
but not rats and mice, naturally develop amyloid plaques and AD. Previous translational 
problems in AD drug discovery might partly be explained by this. 
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5 CONCLUSION AND FUTURE CONSIDERATIONS 
Synaptic dysfunction is emerging as one of the earliest and most severe pathological 
hallmarks of AD (Selkoe 2002). This thesis contributes with knowledge about the synaptic 
localisation of particularly ADAM10 and BACE1, but also of γ-secretase. Moreover, we 
demonstrated that Aβ is continuously secreted from synapses in an activity-independent 
manner and that a 25 kDa CTF is the most abundant APP-derived fragment in human brain as 
opposed to rat and mouse brain where this fragment is barely detectable. 
Although several studies have shown Aβ release to be activity-dependent (Cirrito et al. 2005; 
Tampellini et al. 2009; Kamenetz et al. 2003; Dolev et al. 2013) the mechanism of Aβ 
release is still elusive. We demonstrated that the mechanism of Aβ release is distinct from 
that of normal neurotransmission and concluded that intact cells are necessary for Aβ to be 
secreted from neurons. Nilsson et al. (2013) have demonstrated that conditional knockout of 
autophagy-related gene 7 (Atg7) resulted in reduced Aβ secretion and extracellular plaque 
load, implying a role of autophagy in Aβ secretion. Aβ release also appears to be associated 
with exosomes (Rajendran et al. 2006). We are currently investigating the role of protein 
trafficking and autophagy in the release of Aβ.  
Understanding the mechanism of Aβ secretion is facilitated by understanding its production. 
To that end this thesis has contributed substantially. We showed that both the α-secretase 
ADAM10 and the β-secretase BACE1 are located both pre- and postsynaptically and that 
both enzymes are highly enriched in SVs. However, the activities of these two enzymes have 
contrasting effects since ADAM10 cleavage of APP precludes Aβ formation while BACE1 
cleavage promotes it. Since nature seem to primarily promote the most energy-effective 
processes, it is conceivable that cleavage of APP in SVs is not random. Consequently, still 
unknown regulatory mechanisms probably direct the processing of APP in SVs towards 
either amyloidogenic or non-amyloidogenic processing. Alternatively, ADAM10 and BACE1 
might be present in different SV pools. However, this is fairly unlikely since the highly pure 
SVs in which we detected enrichment of ADAM10 and BACE1 were isolated based both on 
density and size and were thus very homogeneous. Furthermore, since active γ-secretase is 
not enriched in SVs, the CTF-β need to be transported from the SVs to yet another cellular 
location for Aβ to be produced. Consequently, more research is still required in order to fully 
appreciate the regulation and location of APP processing. 
Our finding of considerable species differences in the levels of the 25 kDa CTF is rather 
remarkable. Willem et al. (2015) has pointed out the possibility that the synaptotoxicity of Aβ 
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dimers might actually be attributable to Aη-α, which is produced after ADAM10 processing 
of CTF-η and is of the same size as Aβ dimers. Since the levels of the 25 kDa CTF in rat and 
mouse brain are very low, it is assumable that these animals do not have substantial amounts 
of Aη-α in their brains either. Consequently, they would be expected not to suffer from Aη-α 
and CTF-η induced toxicity. This is yet another reason as to why rats and mice are not to be 
considered optimal models for AD. Much more research should be done in order to enable 
replacement, or at least considerable reduction, of the use of animals in research. A lot is 
already being done in this regard, yet the use of transgenic animals is standardised in this 
field of research which renders it more difficult to develop alternative models.  
It is fascinating that a novel APP processing pathway was identified as recently as 2015 
(Wang et al. 2015; Willem et al. 2015), although the product of this processing had probably 
been observed and reported before (Haass et al. 1992; Tamaoka et al. 1992; Estus et al. 
1992). Aβ was identified in the 1980s and its pivotal role in AD pathology has long been 
recognised (Selkoe 2011). However, there is still no Aβ modifying AD treatment and it is not 
known where Aβ production takes place, nor how the production is regulated or how Aβ 
gains toxicity and exerts its toxic effects. Furthermore, the mechanistic link between Aβ and 
synaptic dysfunction remains elusive. This sheds light on the extremely important role of 
basic research for the advancement of AD research and future development of AD therapies. 
If we do not understand APP processing and the physiological and pathophysiological roles 
of Aβ, we will not cure AD. Yet, however we may be able to alter Aβ levels in the brain, we 
will not cure AD if we do not simultaneously ameliorate the cognitive dysfunction and 
memory loss.  
In summary, development of effective treatment strategies for AD is urgently needed and 
dependent on the findings from basic research. Therefore this thesis facilitates future 
development of AD therapies and is thus of outmost importance for the AD field. 
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